• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

上尿路高级别移行细胞癌的管理

Management of high grade transitional cell cancer of the upper urinary tract.

作者信息

Murphy D M, Zincke H, Furlow W L

出版信息

J Urol. 1981 Jan;125(1):25-9. doi: 10.1016/s0022-5347(17)54881-8.

DOI:10.1016/s0022-5347(17)54881-8
PMID:7463577
Abstract

A total of 175 patients was operated on for grade 2, 3 or 4 transitional cell epithelioma of the upper urinary tract. Followup was between 5 and 26 years. The operations involved total nephroureterectomy, simple nephrectomy and local resection. Patient survival correlated well with tumor stage and, particularly, with tumor grade, and, consistently, was inferior to that of an age and sex-matched control group. The correlation of survival and ipsilateral tumor recurrence with the type of operation suggests that patients with grade 2 tumors may benefit from total nephroureterectomy. The incidence of ipsilateral tumor recurrence (28 per cent) was high in this group. The radical procedure seems to be of no benefit to patients with grade 3 or 4 tumors. The incidence of subsequent bladder tumor was 30 per cent in patients with grades 2 and 3 tumors. The latent period ranged from 2 months to 10 years (average 23 months); 82 per cent of the tumors occurred within 3 years of treatment of the upper tract tumor.

摘要

共有175例患者接受了上尿路2级、3级或4级移行细胞上皮瘤手术。随访时间为5至26年。手术方式包括根治性肾输尿管切除术、单纯肾切除术和局部切除术。患者生存率与肿瘤分期密切相关,尤其是与肿瘤分级相关,并且始终低于年龄和性别匹配的对照组。生存率和同侧肿瘤复发与手术类型的相关性表明,2级肿瘤患者可能从根治性肾输尿管切除术中获益。该组同侧肿瘤复发率较高(28%)。根治性手术似乎对3级或4级肿瘤患者无益。2级和3级肿瘤患者后续发生膀胱肿瘤的发生率为30%。潜伏期为2个月至10年(平均23个月);82%的肿瘤发生在上尿路肿瘤治疗后的3年内。

相似文献

1
Management of high grade transitional cell cancer of the upper urinary tract.上尿路高级别移行细胞癌的管理
J Urol. 1981 Jan;125(1):25-9. doi: 10.1016/s0022-5347(17)54881-8.
2
Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract.上尿路移行细胞癌手术治疗后膀胱内复发的危险因素。
Urology. 2008 Jan;71(1):123-7. doi: 10.1016/j.urology.2007.08.054.
3
Laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma: the Cleveland Clinic experience.腹腔镜根治性肾输尿管切除术治疗上尿路移行细胞癌:克利夫兰诊所的经验
J Urol. 2000 Nov;164(5):1513-22.
4
Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.上尿路移行细胞癌行肾输尿管切除术或输尿管节段切除术后膀胱肿瘤的病理特征。
Urology. 2007 Feb;69(2):251-4. doi: 10.1016/j.urology.2006.09.065.
5
The ureteral stump after nephroureterectomy.肾输尿管切除术后的输尿管残端。
J Urol. 1976 Jun;115(6):654-5. doi: 10.1016/s0022-5347(17)59324-6.
6
Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma.开放性肾输尿管切除术与输尿管镜及经皮治疗上尿路移行细胞癌的比较。
Urology. 2006 Jun;67(6):1181-7. doi: 10.1016/j.urology.2005.12.034.
7
Recurrent urothelial tumors following surgery for transitional cell carcinoma of the upper urinary tract.上尿路移行细胞癌手术后的复发性尿路上皮肿瘤。
Cancer. 1976 Nov;38(5):2173-83. doi: 10.1002/1097-0142(197611)38:5<2178::aid-cncr2820380548>3.0.co;2-1.
8
Risk factors for intravesical recurrence after nephroureterectomy in patients with upper urinary tract urothelial carcinoma.上尿路尿路上皮癌患者肾输尿管切除术后膀胱内复发的危险因素。
Int Urol Nephrol. 2017 Mar;49(3):425-430. doi: 10.1007/s11255-017-1510-5. Epub 2017 Jan 11.
9
Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma.经内镜治疗的上尿路移行细胞癌的长期随访
Urology. 1996 Jun;47(6):819-25. doi: 10.1016/S0090-4295(96)00043-X.
10
Primary grade 1 transitional cell carcinoma of the renal pelvis and ureter.原发性肾盂及输尿管一级移行细胞癌
J Urol. 1980 May;123(5):629-31. doi: 10.1016/s0022-5347(17)56069-3.

引用本文的文献

1
Case Report: Neoadjuvant immunotherapy with pembrolizumab alone for bilateral upper tract urothelial carcinoma is a feasible strategy for kidney sparing and avoidance of hemodialysis.病例报告:单独使用帕博利珠单抗进行新辅助免疫治疗用于双侧上尿路尿路上皮癌是一种可行的保留肾脏及避免血液透析的策略。
Front Oncol. 2022 Sep 23;12:985177. doi: 10.3389/fonc.2022.985177. eCollection 2022.
2
More than meets the eye: A case of synchronous ipsilateral clear cell renal cell carcinoma and urothelial carcinoma of the pelvicalyceal system and literature review.所见不止于表面:同侧肾盂肾细胞癌和尿路上皮癌同时发生一例并文献复习。
Acta Biomed. 2022 Jan 19;92(6):e2021380. doi: 10.23750/abm.v92i6.11768.
3
Pathologically diagnosed incidentaloma transition cell carcinoma (TCC) of renal pelvis in a laproscopic radical nephrectomy specimen done for a lower pole renal mass.
在为下极肾肿物进行的腹腔镜根治性肾切除标本中,经病理诊断为肾盂偶发移行细胞癌(TCC)。
Urol Case Rep. 2021 Feb 11;37:101607. doi: 10.1016/j.eucr.2021.101607. eCollection 2021 Jul.
4
Trends in the utilization of imaging for upper tract urothelial carcinoma.上尿路尿路上皮癌影像学检查的应用趋势
Urol Oncol. 2016 May;34(5):236.e23-8. doi: 10.1016/j.urolonc.2015.12.002. Epub 2016 Jan 21.
5
Distal ureterectomy techniques in laparoscopic and robot-assisted nephroureterectomy: Updated review.腹腔镜及机器人辅助肾输尿管切除术的远端输尿管切除技术:最新综述
Urol Ann. 2015 Jan-Mar;7(1):8-16. doi: 10.4103/0974-7796.148575.
6
Renal cell carcinoma of the kidney with synchronous ipsilateral transitional cell carcinoma of the renal pelvis.肾肾细胞癌伴同侧肾盂同步移行细胞癌。
Case Rep Urol. 2013;2013:194127. doi: 10.1155/2013/194127. Epub 2013 Jun 13.
7
Bipolar plasma vaporization - an innovative intramural ureter detachment method during nephroureterectomy.双极等离子汽化——肾输尿管切除术期间一种创新的壁内输尿管分离方法。
J Med Life. 2012 Jun 12;5(2):153-6. Epub 2012 Jun 18.
8
Squamous cell carcinoma of kidney co-existing with renal calculi: a rare tumour.肾鳞状细胞癌合并肾结石:一种罕见肿瘤。
BMJ Case Rep. 2011 Mar 1;2011:bcr1020103388. doi: 10.1136/bcr.10.2010.3388.
9
A rare cause of renal mass; a case study.罕见的肾肿块病因;病例研究。
Libyan J Med. 2009 Dec 1;4(4):164-5. doi: 10.4176/090803.
10
Laparoscopic nephroureterectomy: the distal ureteral dilemma.腹腔镜肾输尿管切除术:输尿管远端的困境
Adv Urol. 2009;2009:316807. doi: 10.1155/2009/316807. Epub 2008 Nov 5.